A retro-inverso miniantibody with anti-HIV activity

AIDS Research and Human Retroviruses

Volumn 16, Issue 1, 2000, Pages 59-65

  Levi, Michael ^a,b   Hinkula, Jorma ^a   Wahren, Britta ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; SYNTHETIC PEPTIDE;

AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

AMINO ACID SEQUENCE; AMINOPEPTIDASES; ANIMALS; CHROMOSOME MAPPING; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; IMMUNOGLOBULIN VARIABLE REGION; MICE; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS;

EID: 0033987549     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922200309601     Document Type: Article

References (21)

1. 1. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, and Volberding PA: Anti-retroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA 1996;276:146-154.
2. 2. Åkerblom L, Hinkula J, Broliden PA, Mäkitalo B, Fridberger, T, Rosen J, Villacres-Eriksson M, Morein B, and Wahren B: Neutralizing cross reactive and non-neutralizing antibodies to HIV-1 gp120. AIDS 1990;4:953-960.
3. 3. Barbas CF III, Björling E, Chiodi F, Dunlop N, Cababa D, Jones TM, Zebedee SL, Persson MA, Nara PL, Norrby E, et al.: Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci USA 1992;89: 9339-9343.
4. 4. Hinkula J, Bratt G, Gilljam G, Nordlund S, Broliden PA, Holmberg V, Olausson-Hansson E, Albert J, Sandström E, and Wahren B: Immunological and virological interactions in patients receiving passive immunotherapy with HIV-1 neutralizing monoclonal antibodies. J AIDS 1994;7:940-951.
5. 5. Levi M, Sällberg M, Rudén U, Herlyn D, Maruyama H, Wigzell H, Marks J, and Wahren B: A complementarity-determining region synthetic peptide acts as a miniantibody and neutralizes human immunodeficiency virus type 1 in vitro. Proc Natl Acad Sci USA 1993;90:4374-4378.
6. 6. Briand J-P, Benkirane N, Guichard G, Newman JF, Van Regenmortel MH, Brown F, and Muller S: A retro-inverso peptide corresponding to the GH loop of foot-and-mouth disease virus elicits high levels of long-lasting protective neutralizing antibodies. Proc Natl Acad Sci USA 1997;94:12545-12550.
7. 7. Carver JA, Esposito G, Viglino P, Fogolari F, Guichard G, Briand JP, Van Regenmortel MH, Brown F, and Mascagni P: Structural comparison between retro-inverso and parent peptides: molecular basis for the biological activity of a retro-inverso analogue of the immunodominant fragment of VP1 coat protein from foot-and-mouth disease virus. Biopolymers 1997;41:569-590.
8. 8. Muller S, Briand J-P, Benkirane N, Guichard G, Van Regenmortel MHV, Newman JFE, and Brown F: Antigenic mimicry with an all-D-retro peptide corresponding to the immunodominant loop of foot-and-mouth disease virus. In: Vaccines 97. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1997, pp. 17-22.
9. 9. Moore JP and Sodroski J: Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 1996;70:1863-1872.
10. 10. Levi M, Hinkula J, and Wahren B: Anti-idiotypic antibodies in HIV infected patients to a neutralizing MAb and its complementarity determining regions. In: Idiotypes in Medicine: Autoimmunity, Infection and Cancer (Shoenfeld Y, Kennedy RC, and Ferrone S, eds.). Elsevier Science, 1997, p. 407-414.
11. 11. Albert J, Stålhandske P, Marquina S, Karis J, Fouchier RA, Norrby E, and Chiodi F: Biological phenotype of HIV type 2 isolates correlates with V3 genotype. AIDS Res Hum Retroviruses 1996; 12:821-828.
12. 12. Welling GW, Van Gorkum J, Darnhof RA, and Drijhout JW: A ten-residue fragment of an antibody (mini-antibody) directed against lysozyme as ligand in immunoaffinity chromatography. J Chromatogr 1991;548:235-242.
13. 13. Williams WV, Kieber-Emmons T, VonFeldt JM, Greene MI, and Weiner DB: Design of bioactive peptides based on antibody hypervariable region structures. Development of conformationally constrained and dimeric peptides with enhanced affinity. J Biol Chem 1991;266:5182-5190.
14. 14. Fontenot JD, Zacharopoulos VR, and Phillips DM: Proline-rich tandem repeats of antibody complementarity-determining regions bind and neutralize human immunodeficiency virus type 1 particles. J Virol 1996;70:6557-6562.
15. 15. Millar AL, Jackson NA, Dalton H, Jennings KR, Levi M, Wahren B, and Dimmock NJ: Rapid analysis of epitope-paratope interactions between HIV-1 and a 17-amino-acid neutralizing microantibody by electrospray ionization mass spectrometry. Eur J Biochem 1998;258:164-169.
16. 16. Broliden PA, Ljunggren K, Hinkula J, Norrby E, Åkerblom L, and Wahren B: A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization. J Virol 1990;64:936-940.
17. 17. Jackson NAC, Levi M, Wahren B, and Dimmock NJ: Properties and mechanism of action of a 17 amino acid, V3 loop-specific microantibody that binds to and neutralizes human immunodeficiency virus type 1 virions. J Gen Virol 1999;80:225-236.
18. 18. Lasonder E, Bloemhoff W, and Welling GW: Interaction of lysozyme with synthetic anti-lysozyme D1.3 antibody fragments studied by affinity chromatography and surface plasmon resonance. J Chromatogr 1994;676:91-98.
19. 19. Sivolapenko GB, Douli V, Pectasides D, Skarlos D, Sirmalis G, Hussain R, Cook J, Courtenay-Luck NS, Merkouri E, Konstantinides K, et al. Breast cancer imaging with radiolabelled peptide from complementarity-determining region of anti tumour antibody. Lancet 1995;346:1662-1666.
20. 20. Bourgeois C, Bour JB, Aho LS, and Pothier P: Prophylactic administration of a complementarity-determining region derived from a neutralizing monoclonal antibody is effective against respiratory syncytial virus infection in BALB/c mice. J Virol 1998;72:807-810.
21. 21. Monnet C, Laune D, Laroche-Traineau J, Biard-Piechaczyk M, Briant L, Bes C, Pugniere M, Mani JC, Pau B, Cerutti M, Devauchelle G, Devaux C, Granier C, and Chardes T: Synthetic peptides derived from the variable regions of an anti-cd4 monoclonal antibody bind to CD4 and inhibit HIV-1 promoter activation in virus-infected cells. J Biol Chem 1999;274:3789-3796.